Ironwood Pharmaceuticals, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; filed May 10, 2016. Financial statements are unaudited. Ironwood is a commercial biotechnology company whose primary commercial product is linaclotide, marketed in the U.S. as LINZESS with Allergan.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 / comparator |
|---|---|---|
| Collaborative arrangements revenue | $66.0 million | $28.9 million; up 128% |
| Research and development expense | $31.8 million | $26.6 million |
| Selling, general and administrative expense | $36.2 million | $30.3 million |
| Operating loss | $2.0 million | $28.1 million |
| Net loss | $13.3 million | $33.2 million |
| Basic and diluted net loss per share | $0.09 | $0.24 |
| Net cash from operating activities | $0.2 million | $(35.8) million |
- Revenue growth principally reflected a $21.5 million increase in Ironwood’s U.S. LINZESS net-profit share and a $12.9 million Astellas development milestone following its Japanese NDA filing. Additional increases included API shipments and Cologuard and VIBERZI co-promotion revenue.
- LINZESS U.S. collaboration revenue was $46.6 million; Ironwood’s reported share of net profit after its related selling costs was $37.5 million.
- Other expense was $11.3 million, including $9.9 million interest expense and $1.6 million derivative loss. Interest expense rose $4.7 million year over year, largely due to the 2022 convertible notes.
- At March 31, cash and cash equivalents were $280.9 million and available-for-sale securities were $153.5 million, totaling $434.5 million of unrestricted cash, cash equivalents and securities. Total assets were $603.3 million; stockholders’ equity was $90.9 million.
- Debt principal was approximately $491.5 million, per management’s risk disclosure. The balance sheet reported $223.9 million carrying value for the 2022 convertible notes and $152.9 million carrying value for PhaRMA notes. The 2022 notes bear 2.25% cash interest and mature in 2022; the PhaRMA notes bear 11% and are repaid partly from LINZESS U.S. sales-linked payments.
Material changes and notable items
- Revenue more than doubled year over year, while net loss narrowed by $19.9 million. Operating expenses increased 19%, including higher pipeline, facility, personnel and commercial costs.
- Operating cash flow improved to slightly positive from a $35.8 million use in Q1 2015. Cash and securities together decreased approximately $4.9 million during the quarter, primarily reflecting PhaRMA principal payments and capital expenditures.
- Q1 2016 rent expense for headquarters, net of sublease income, was $5.5 million versus $1.5 million a year earlier. It included a $3.5 million charge for estimated obligations on sublet space, following a lease estimate change tied to CPI and fair-market rent.
- In April 2016, Ironwood agreed to license U.S. rights to lesinurad products, including Zurampic, for a $100 million upfront payment, single-digit royalties and potential milestones of up to $165 million. Closing was expected in Q2 2016, subject to antitrust waiting-period clearance; this was a subsequent event, not a Q1 transaction.
Outlook, commentary and risks
- Management said available cash was expected to fund projected operating needs for at least the next 12 months. It aims to become cash-flow positive but had not achieved positive operating cash flow historically; no specific quarterly or annual financial guidance was provided.
- Management expected substantial R&D and SG&A spending to continue. It anticipated a possible U.S. launch of the 72 mcg LINZESS dose for CIC in 2017, subject to FDA approval.
- Ironwood announced it would discontinue IW-9179 development for gastroparesis after an exploratory Phase IIa study did not meaningfully reduce symptom severity. Development for functional dyspepsia was still being assessed.
- Key risks include dependence on LINZESS and Allergan, reimbursement and pricing pressure, partner and contract-manufacturer performance, regulatory and clinical uncertainty, product safety, competition, and debt service. The company also disclosed approximately $10.1 million accrued for excess linaclotide API purchase commitments.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Underlying LINZESS U.S. sales and the sustainability of Ironwood’s collaboration profit share, including the cost-sharing calculations reported by Allergan.
- Progress and regulatory outcomes for the 72 mcg LINZESS sNDA, Japanese linaclotide review, and other pipeline programs.
- Available liquidity and debt-service needs, particularly PhaRMA payments linked to LINZESS sales and the planned $100 million lesinurad upfront payment.
- Closing and integration of the lesinurad transaction, including transition, supply, commercialization and post-marketing requirements.
- Potential effects of the sublease obligations, API purchase commitments, and future changes in derivative valuations or collaboration milestones.